-+ 0.00%
-+ 0.00%
-+ 0.00%

AULOS BIOSCIENCE’S IMNESKIBART DEMONSTRATES OUTSTANDING PHASE 2 ACTIVITY IN CHECKPOINT INHIBITOR-REFRACTORY MELANOMA AND LUNG CANCER, COMPARING FAVORABLY WITH HISTORICAL TREATMENT BENCHMARKS

Reuters·11/06/2026 14:10:18

Please log in to view news